Janssen persuades Scotland to reimburse Zytiga
This article was originally published in Scrip
Executive Summary
Janssen has managed to convince the Scottish Medicines Consortium, Scotland's health technology appraisal body, that the benefits of its anticancer Zytiga (abiraterone) do in fact justify the cost. The consortium has this week accepted the drug for use on the Scottish NHS for patients with metastatic castration resistant prostate cancer.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.